Managing side effects without abandoning the protocol Nausea is the side effect that causes the most people to quit semaglutide, and in many cases, it is manageable with straightforward adjustments
Not indicated for diabetes in this setting
On average, people taking GLP-1 Treatments, Semaglutide or Tirzepatide eat about 30% less food than they would otherwise
Some patients achieve satisfactory weight loss at intermediate doses (1.0 or 1.7 mg) and may not need to escalate to the full 2.4 mg dose
Researchers exploring retatrutide for both weight management and glycemic control can find additional protocol details in the timeline to results guide
In many cases, what happens is: finish your current cycle of tirzepatide (or reduce to a stable dose), then after a defined interval (often one week or so) begin retatrutide at the low dose under provider monitoring